Since SAA is common in chronic obstructive pulmonary disease (COPD) and lung cancer, it can predict the severity of these two diseases, and has been identified as a biomarker of lung cancer severity and a potential target for treatment [40,41,42]. This evidence concerns the gene SAA1 and lung carcinoma.